218 related articles for article (PubMed ID: 31769277)
1. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
Wang H; Zhou H; Zhang Z; Geng C; Chen W
Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
[TBL] [Abstract][Full Text] [Related]
2. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Characteristics and Survival Analysis of Patients with Plasma Cell Leukemia].
Wang SF; Qin XQ; Guo QH; Wang JY; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):693-698. PubMed ID: 37356928
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
6. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
[No Abstract] [Full Text] [Related]
7. Genetic aberrations and survival in plasma cell leukemia.
Tiedemann RE; Gonzalez-Paz N; Kyle RA; Santana-Davila R; Price-Troska T; Van Wier SA; Chng WJ; Ketterling RP; Gertz MA; Henderson K; Greipp PR; Dispenzieri A; Lacy MQ; Rajkumar SV; Bergsagel PL; Stewart AK; Fonseca R
Leukemia; 2008 May; 22(5):1044-52. PubMed ID: 18216867
[TBL] [Abstract][Full Text] [Related]
8. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
[TBL] [Abstract][Full Text] [Related]
10. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
11. Single-center experience of patients with plasma cell leukemia in the era of new therapeutics.
Dampmann M; Flossdorf S; Keyl J; Reinhardt HC; Hanoun C
Acta Haematol; 2024 May; ():. PubMed ID: 38763126
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents.
Talamo G; Dolloff NG; Sharma K; Zhu J; Malysz J
Rare Tumors; 2012 Jun; 4(3):e39. PubMed ID: 23087795
[TBL] [Abstract][Full Text] [Related]
14. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
Wang H; Li JY; Sun C; Zhou X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
[TBL] [Abstract][Full Text] [Related]
15. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A;
Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060
[TBL] [Abstract][Full Text] [Related]
16. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
D'Arena G; Valentini CG; Pietrantuono G; Guariglia R; Martorelli MC; Mansueto G; Villani O; Onofrillo D; Falcone A; Specchia G; Semenzato G; Di Renzo N; Mastrullo L; Venditti A; Ferrara F; Palumbo A; Pagano L; Musto P
Ann Oncol; 2012 Jun; 23(6):1499-502. PubMed ID: 22039089
[TBL] [Abstract][Full Text] [Related]
17. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
19. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
Kupsh A; Arnall J; Voorhees P
J Oncol Pharm Pract; 2020 Jul; 26(5):1274-1278. PubMed ID: 31865846
[TBL] [Abstract][Full Text] [Related]
20. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
Katodritou E; Kastritis E; Dalampira D; Delimpasi S; Spanoudakis E; Labropoulou V; Ntanasis-Stathopoulos I; Gkioka AI; Giannakoulas N; Kanellias N; Papadopoulou T; Sevastoudi A; Michalis E; Papathanasiou M; Kotsopoulou M; Sioni A; Triantafyllou T; Daiou A; Papadatou M; Kyrtsonis MC; Pouli A; Kostopoulos I; Verrou E; Dimopoulos MA; Terpos E
Am J Hematol; 2023 May; 98(5):730-738. PubMed ID: 36869876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
